17-beta estradiol (E2, Estrace, Estinyl, Delestrogen, Elestrin, Evamist, Imvexxy)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Estrace, Delestrogen Delestrogen. Estradiol cypionate & estradiol valerate.

Indications

Dosage

  • moderate to severe vasomotor symptoms
    • cypionate 1-5 mg IM every 3-4 weeks
    • valerate 10-20 mg IM every 4 weeks
  • osteoporosis prevention
    • 1-2 mg PO QD for 1st 3 weeks of month
  • hypogonadism:
    • 1-2 mg PO QD for 1st 3 weeks of month
    • cypionate: 1.5-2 mg/month IM
    • valerate: 10-20 mg/month
  • prostate cancer:
    • > 30 mg estradiol valerate every 1-2 weeks
    • 1-2 mg PO TID

Tabs: 0.5, 1, 2 mg. Injection (cypionate): 5 mg/mL (5 mL) (valerate): 20 mg/mL, 40 mg/mL syringe 2.5-3 mL, needle 22 g, 1.5 inch

Topical:vaginal cream (Estrace) 42 gram tube atrophic vaginitis:

  • 2-4 g/day for 2 weeks
  • reduce to 1-2 g for 2 weeks
  • maintenance 1 g 3x/week

Gel: Elestrin (bioidentica) postmenopausal vasomotor symptoms

Evamist: transdermal spray, 1.53 mg/spray

Vaginal rings: see Estring, Femring

Pharmacokinetics

elimination via liver

elimination via kidney

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

More specific terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 Department of Veterans Affairs, VA National Formulary
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Prescriber's Letter 8(7):41 2001
  5. Prescriber's Letter 15(4): 2008 Estrogen-Containing Hormone Replacement Products for Postmenopausal Women Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=240407&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 6.2 Deprecated Reference
  7. 7.0 7.1 Brown T FDA Approves Imvexxy for Moderate to Severe Dyspareunia. Medscape - May 31, 2018. https://www.medscape.com/viewarticle/897436

Database